Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)

NCT07527195 · Recruiting

Last updated 2026-05-28

This clinical trial is testing how the medications CagriSema, cagrilintide, and semaglutide affect muscle health in adults with obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 100 people Planned (estimated).

Who can join Ages 50–70 · all sexes

Timeline Started 2026-04 · est. completion 2028-06

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT07527195 ↗

Description as written by the study sponsor.

The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than normal blood sugar as they lose weight. Participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to treat people with type 2 diabetes and excess body weight) or placebo (a placebo looks like the treatment being tested but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants will be in this clinical study up to 15 months.

Treatments tested

Cagrilintide Drug

Participants will receive cagrilintide subcutaneously.
Semaglutide Drug

Participants will receive semaglutide subcutaneously.
Placebo cagrilintide Drug

Participants will receive placebo matched to cagrilintide subcutaneously.
Placebo semaglutide Drug

Participants will receive placebo matched to semaglutide subcutaneously.

Main thing measured	Change in insulin-stimulated fluorodeoxyglucose (FDG) uptake in skeletal muscle
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	semaglutide, cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07527195 ↗